Literature DB >> 10800398

h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.

K Watanabe1, T Tajino, M Sekiguchi, T Suzuki.   

Abstract

Caldesmon is a protein widely distributed in smooth and non-smooth muscle cells and is thought to regulate cellular contraction. Its isoform, high-molecular-weight caldesmon (h-CD), was demonstrated to be specific for smooth muscle cells and smooth muscle tumors of the soft tissue and to never be expressed in myofibroblasts. We performed an immunohistochemical study to examine h-CD expression in the following bone tumors: conventional and non-conventional osteosarcoma, 13; malignant fibrous histiocytoma of bone, 5; giant cell tumors of bone, 5; chondroblastoma, 3; metastatic leiomyosarcoma, 2; and rhabdomyosarcoma, 1. Frequent immunoreactivity for muscle actin (alpha-smooth muscle actin or muscle-specific actin) was seen in 11 of 13 osteosarcomas and all other tumors, whereas h-CD was expressed intensely only in 2 leiomyosarcomas. h-CD is considered a specific and useful marker to distinguish smooth muscle tumor from bone tumors with myoid differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800398     DOI: 10.1309/jnqx-f4km-q0q0-7xk8

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  High molecular weight caldesmon positive stromal cells in the capsule of thyroid follicular tumours and tumour-like lesions.

Authors:  H Nakayama; H Enzan; E Miyazaki; T Moriki; H Kiyoku; M Toi; N Kuroda; M Hiroi
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  A rare case of low-grade myofibroblastic sarcoma of the femur in a 38-year-old woman: a case report.

Authors:  Raman Arora; Ruchika Gupta; Alok Sharma; Amit K Dinda
Journal:  J Med Case Rep       Date:  2010-04-28

3.  CAM5.2-positive subserosal myofibroblasts in appendicitis.

Authors:  Tadashi Hamauzu; Naoto Kuroda; Limei Guo; Eriko Miyazaki; Yoshihiro Hayashi; Makoto Toi; Makoto Hiroi; Hideaki Enzan
Journal:  Med Mol Morphol       Date:  2006-12-21       Impact factor: 2.309

4.  Inflammatory myofibroblastic tumor of bone: two cases occurring in long bone.

Authors:  Jianyu Chen; Haigang Li; Zehong Yang; Qingyu Liu; Ming Gao; Xinhua Jiang; Zhaoxi Cai; Biling Liang; Yebin Jiang
Journal:  Skeletal Radiol       Date:  2010-07-22       Impact factor: 2.199

5.  Smooth muscle actin expression in primary bone tumours.

Authors:  F Hemingway; T G Kashima; G Mahendra; A Dhongre; P C W Hogendoorn; F Mertens; N A Athanasou
Journal:  Virchows Arch       Date:  2012-04-28       Impact factor: 4.064

Review 6.  Leiomyosarcoma of the Nasal Cavity and Paranasal Sinuses: A Case Report and Comprehensive Review of the Literature.

Authors:  Sumita S Sam; Brian Stewart; Elham Nasri; Marino E Leon; Ernesto Martinez Duarte
Journal:  Head Neck Pathol       Date:  2022-02-14

7.  Primary right ventricular osteosarcoma.

Authors:  Li Zhang; Jennifer Ellis; Dhruv Kumar; Tom Deng
Journal:  Can J Cardiol       Date:  2008-03       Impact factor: 5.223

8.  Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.

Authors:  Sébastien Salas; Catherine Bartoli; Jean-Laurent Deville; Jean Gaudart; Fréderic Fina; Arlette Calisti; Gérard Bollini; Georges Curvale; Jean-Claude Gentet; Florence Duffaud; Dominique Figarella-Branger; Corinne Bouvier
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

9.  Distribution and role of myofibroblasts in human normal seminal vesicle stroma.

Authors:  Nobuyuki Shimasaki; Naoto Kuroda; Eriko Miyazaki; Yoshihiro Hayashi; Makoto Toi; Makoto Hiroi; Hideaki Enzan; Taro Shuin
Journal:  Med Mol Morphol       Date:  2007-12-21       Impact factor: 2.309

10.  Up-regulated expression of l-caldesmon associated with malignancy of colorectal cancer.

Authors:  Kyung-Hee Kim; Seung-Gu Yeo; Won Ki Kim; Dae Yong Kim; Hyun Yang Yeo; Jun Pyu Hong; Hee Jin Chang; Ji Won Park; Sun Young Kim; Byung Chang Kim; Byong Chul Yoo
Journal:  BMC Cancer       Date:  2012-12-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.